Ipilimumab is a type of medication known as an immune checkpoint inhibitor. It works by helping your immune system recognize and attack cancer cells more effectively. In this trial, Ipilimumab is being tested to see if it can improve the treatment of liver cancer when added to other medications.

Atezolizumab is another immune checkpoint inhibitor. It helps your immune system fight cancer by blocking a protein that prevents your immune cells from attacking cancer cells. This medication is already used in treating some types of cancer, and the trial is exploring its effectiveness in liver cancer.

Bevacizumab is a medication that works by blocking the growth of blood vessels that supply nutrients to tumors. By cutting off the blood supply, it can help slow down or stop the growth of cancer. In this trial, Bevacizumab is being used in combination with other medications to see if it can improve outcomes for patients with liver cancer.

Hepatocellular carcinoma – Hepatocellular carcinoma is a type of liver cancer that originates in the hepatocytes, the main type of liver cell. It typically begins as a single tumor that grows larger over time, but it can also start as multiple small cancer nodules throughout the liver. As the disease progresses, it can invade nearby blood vessels and spread to other parts of the body, such as the lungs and bones. The progression of hepatocellular carcinoma is often associated with underlying liver conditions, such as cirrhosis or chronic hepatitis infection. Symptoms may include abdominal pain, weight loss, and jaundice, which can worsen as the disease advances. The growth rate and pattern of spread can vary significantly among individuals.